THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy (THUNDER2)
Neoadjuvant chemoradiation therapy (nCRT) is the standard treatment modality for locally advanced rectal cancer (LARC), and patients achieving complete response (CR) generally have improved local control, metastasis-free survival, and overall survival.
The aim of this clinical trial is to investigate the impact of radiotherapy dose escalation in rectal cancer by identifying poor responders during treatment using the Early Tumor Regression Index (ERI). Patients are treated using magnetic resonance-guided radiotherapy (MRgRT). ERI is calculated at fraction 10. Patients with an ERI value below 13.1 continue the standard treatment schedule, whereas patients with an ERI value above 13.1 undergo adaptive replanning with dose escalation up to 60.1 Gy to the residual tumor volume.
Concomitant chemotherapy consists of fluoropyrimidine-based treatment, with oxaliplatin permitted in patients at high risk of recurrence. In selected high-risk patients, consolidation chemotherapy with three cycles of FOLFOX may be administered during the interval before surgery.
Following protocol amendments, the study was expanded to include a total planned enrollment of 179 patients. Additional blood samples for circulating tumor DNA (ctDNA) analysis and stool samples for gut microbiome profiling are collected at predefined time points. These longitudinal multi-omics data are integrated with magnetic resonance imaging-based delta-radiomics features to develop composite biomarker models for prediction of treatment response.
The primary outcome measures are complete response, defined as ypT0N0 after Total Mesorectal Excision (TME), ypT0 ycN0 after Local Excision (LE), or ycT0N0 in patients managed with Watch and Wait, and the prospective validation of the magnetic resonance-guided radiotherapy delta-radiomics predictive model.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Neoadjuvant chemoradiation therapy (nCRT) is the standard treatment modality for locally advanced rectal cancer (LARC). Patients who achieve a complete response (CR) after treatment generally experience improved local control, metastasis-free survival, and overall survival. Because response to radiotherapy is dose-dependent in rectal cancer, dose escalation may increase complete response rates. The ability to identify patients who are unlikely to achieve a complete response before surgery or during treatment is therefore of major clinical importance. An Early Tumor Regression Index (ERI) has been developed to predict pathological complete response after nCRT. Patients with ERI values below 13.1 have been shown to demonstrate a stronger response during treatment and a lower probability of developing distant relapse.
The primary aim of this clinical trial is to evaluate the impact of adaptive radiotherapy dose escalation in rectal cancer by identifying poor responders during treatment using ERI and increasing the prescribed radiation dose in these patients. Using this adaptive boosting strategy, an increase of approximately 10% in the complete response rate is expected. All enrolled patients receive chemoradiotherapy delivered using a 0.35 Tesla magnetic resonance-guided radiotherapy (MRgRT) system.
The radiotherapy schedule consists of 55 Gy in 25 fractions to the gross tumor volume and corresponding mesorectum, together with 45 Gy in 25 fractions to the whole pelvis. Concomitant chemotherapy consists of continuous oral capecitabine or 5-fluorouracil. Oxaliplatin may be added in patients considered at high risk of recurrence. Daily magnetic resonance imaging is performed throughout treatment. ERI is calculated at fraction 10. Patients with an ERI value below 13.1 continue the standard treatment schedule, whereas patients with an ERI value above 13.1 undergo adaptive treatment replanning with dose escalation up to 60.1 Gy to the residual tumor volume. For selected high-risk patients, consolidation chemotherapy with three cycles of the FOLFOX regimen may be administered during the interval before surgery. Patients achieving a complete clinical response may be managed using a Watch-and-Wait strategy according to multidisciplinary team evaluation.
Following protocol amendments, the study has been expanded to include additional patients for longitudinal multi-omics analyses. Stool samples are collected for gut microbiome characterization, including metagenomic, metabolomic, and metatranscriptomic analyses. Blood samples are collected for circulating tumor DNA (ctDNA) analyses and other blood-based biomarkers. These data are integrated with magnetic resonance imaging-derived delta-radiomics features to develop composite biomarker models aimed at improving prediction of treatment response and supporting personalized treatment strategies in locally advanced rectal cancer.
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Giuditta Chiloiro, MD PhD
- Numero di telefono: + 39 3934360389
- Email: giuditta.chiloiro@policlinicogemelli.it
Luoghi di studio
-
-
Roma
-
Roma, Roma, Italia, 00168
- Reclutamento
- Fondazione Policlinico Universitario A.Gemelli IRCCS
-
Contatto:
- Margherita Zona
- Numero di telefono: +39 0630156261
- Email: margherita.zona@policlinicogemelli.it
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Descrizione
Inclusion Criteria:
- Histological proven adenocarcinoma of the rectum;
- cT2-4, or cN0-2 (also extramesorectal nodes), or mesorectal fascia involvement for tumor (MRF+) or extramural venous invasion (EMVI+);
- cM0;
- No prior radiotherapy in pelvic region;
- Tumour located between 0 and 15 cm above the anal verge;
- Not mesorectal fascia involvement for tumor;
- No extramesorectal nodes involvement;
- No extramural venous invasion (EMVI);
- No rectal mucinous adenocarcinoma histology;
- No contra-indications for MRI;
- ECOG 0-1;
- Age over 18 years;
- Adequate hematological function: granulocyte count > 1500/microl, Hemoglobin level > 10 g/dl, Platelet count > 100000/microl, ALT/AST: 7-45 UI/L;
- No other malignancies in the previous history (except skin and initial cervical cancer);
- Absence of important comorbidities: severe cardiac or coagulative disease, moderate or severe restrictive/obstructive lung deficit, severe cognitive impairment, moderate and severe renal and hepatic impairment;
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;
- Absence of pregnancy or lactating female patients;
- Written informed consent.
Exclusion Criteria:
- Distant metastases (cM1);
- Prior radiotherapy in the pelvic region;
- Tumour located lower than 0 cm or higher than 15 cm above the anal verge;
- Rectal mucinous adenocarcinoma histology;
- Contra-indications for Magnetic Resonance Imaging (MRI);
- Eastern Cooperative Oncology Group (ECOG) performance status score >= 2;
- Age under 18 years;
- Inadequate hematological function (Granulocyte count <= 1500/microl, Hemoglobin level <= 10 g/dl, Platelet count <= 100000/microl, ALT/AST outside 7-45 UI/L);
- History of other malignancies (except skin cancer and initial cervical cancer);
- Presence of severe comorbidities (severe cardiac or coagulative disease, moderate or severe restrictive/obstructive lung deficit, severe cognitive impairment, moderate/severe renal or hepatic impairment);
- Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule;
- Pregnant or lactating female patients.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: LARC patients treated by MRgRT with Early Regression Index (ERI) at 10th fraction >13.1
All patients will be treated on MRgRT, at the second week , patients with an ERI > 13.1 will underwent RT dose intensification on GTV + 3 mm to 60.1 Gy with a Simultaneous Integrated Boost (SIB).
|
The initial radiotherapy treatment will consist in delivering 55 Gy in 25 fractions on GTV plus the corresponding mesorectum of 45Gy in 25 fractions on the whole pelvis.
Chemotherapy with 5-fluorouracil (5-FU) or oral capecitabine will be administered continuously.
A 0.35 Tesla Magnetic resonance image will be acquired at simulation and every day during MRgRT.
At fraction 10, ERI will be calculated.
If ERI will be inferior than 13.1 the patient will continue the original treatment.
If ERI will be higher than 13.1 the treatment plan will be reoptimized considering the residual tumor at fraction 10 as new therapy volume, where the dose will be intensified to reach 60.1 Gy.
|
|
Nessun intervento: LARC patients treated by MRgRT with Early Regression Index (ERI) at 10th fraction < 13.1
All patients will be treated on MRgRT, at the second week , patients with an ERI < 13.1 will underwent standard RT dose of 55Gy on tumor and corresponding mesorectum
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Complete response
Lasso di tempo: 6 months
|
ypT0N0 in case of TME, ypT0ycN0 in case of LE, ycT0N0 in case of WW
|
6 months
|
|
Prospective validation of delta radiomics MR-guide Radiotherapy model
Lasso di tempo: 6 months
|
correlation between response prediction and clinical or pathological response
|
6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
3 years Local control
Lasso di tempo: 3 years follow up
|
survival outcomes
|
3 years follow up
|
|
3 years Metastasis Free Survival
Lasso di tempo: 3 years follow up
|
survival outcomes
|
3 years follow up
|
|
3 years Disease Free Survival
Lasso di tempo: 3 years follow up
|
survival outcomes
|
3 years follow up
|
|
3 years Overall Survival
Lasso di tempo: 3 years follow up
|
survival outcomes
|
3 years follow up
|
|
R0 resection rate
Lasso di tempo: 6 months
|
percentage of surgical intervention with negative margins
|
6 months
|
|
Tumor Regression Grade 2
Lasso di tempo: 6 months
|
surgical outcomes
|
6 months
|
|
Neoadjuvant rectal (NAR) score
Lasso di tempo: 6 months
|
surgical outcomes
|
6 months
|
|
Tumor Regression Grade 1
Lasso di tempo: 6 months
|
surgical outcomes
|
6 months
|
|
Sphincter preservation rate
Lasso di tempo: 6 months
|
percentage of surgical intervention without the positioning of permanent stomia
|
6 months
|
|
Organ preservation rate
Lasso di tempo: 3 years follow up
|
percentage of patients underwent conservative approaches (WW or EL)
|
3 years follow up
|
|
Rectal function
Lasso di tempo: 3 years follow up
|
impact of therapy on rectal functions by MSKCC questionnaire (from always to never with 5 items)
|
3 years follow up
|
|
Sexual function
Lasso di tempo: 3 years follow up
|
impact of therapy on sexual function by IIEF and FSFI questionnaires (from 1 worst to 5 better)
|
3 years follow up
|
Collaboratori e investigatori
Collaboratori
Investigatori
- Investigatore principale: Giuditta Chiloiro, MD PhD, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 3460
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro del retto localmente avanzato
-
Yonsei UniversityNon ancora reclutamentoRAS/BRAF Wild-Type Advanced Cancer MathementCorea, Repubblica di
-
Second Affiliated Hospital, School of Medicine,...Attivo, non reclutanteElettroacopuntura combinata con paclitaxel legato alla proteina e anticorpo PD-1 per il trattamento di seconda linea di HER2 negativo, PMMR/MSS Advanced Gastric CancerCina